breast cancer
Oncology · 2006–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bevacizumab Multiple cancer indications: metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small… | Mar 2024 | Recommended | 1 individuals Medical Oncology Group |
| zoledronic acid Adjuvant management of breast cancer in post-menopausal women. | Jul 2023 | Recommended | no section in document |
| goserelin Preservation of fertility in premenopausal women with breast cancer undergoing chemotherapy to reduce chemotherapy-induced menopause. | Nov 2016 | Deferred | input received Breast Cancer Network Australia |
| netupitant + palonosetron Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy and anthracycline plus… | Nov 2015 | Recommended with restriction | none received |
| anastrozole, everolimus, exemestane, goserelin, letrozole Breast cancer (hormone receptor positive, HER2 negative) in patients who are not pre-menopausal, and prostate cancer and endometriosis indications for… | Nov 2014 | Recommended | no section in document |
| eribulin mesilate Treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease,… | Mar 2013 | Not recommended | unclear |
| eribulin mesilate Treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease,… | Nov 2013 | Recommended with restriction | unclear |
| docetaxel Adjuvant treatment of operable breast cancer in combination with cyclophosphamide. | Nov 2009 | Recommended with restriction | no section in document |
| paclitaxel Metastatic breast cancer after failure of prior therapy which includes an anthracycline. | Nov 2008 | Not recommended | no section in document |
| aprepitant Management of nausea and vomiting associated with cytotoxic chemotherapy in patients undergoing treatment for breast cancer with cyclophosphamide and an… | Mar 2006 | Recommended with restriction | no section in document |
| aprepitant Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat breast cancer, in combination with a 5HT3 antagonist and… | Mar 2006 | Recommended with restriction | no section in document |
| pegfilgrastim Primary prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer undergoing adjuvant chemotherapy with docetaxel in combination with an… | Nov 2006 | Recommended with restriction | no section in document |
| pegfilgrastim Primary prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer undergoing adjuvant chemotherapy with docetaxel in combination with an… | Nov 2006 | Recommended with restriction | no section in document |
Who spoke
Medical Oncology Group · Breast Cancer Network Australia
What the PBS pays
$207M in government benefit over 2024–25, across 1,344,029 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| anastrozole, everolimus, exemestane, goserelin, letrozole | $94.2M |
| goserelin | $60.7M |
| paclitaxel, nanoparticle albumin-bound | $16.4M |
| netupitant and palonosetron | $15M |
| docetaxel | $4.9M |
| Pegfilgrastim | $4.3M |
| pegfilgrastim | $4.3M |
| zoledronic acid | $3.7M |
| eribulin mesilate | $3.4M |
| aprepitant | $0.1M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 1 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| eribulinEribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen | TA515 | not recommended | 2018-03 |
| eribulinEribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens | TA423 | recommended restricted | 2016-12 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| thiotepaTEPADINA thiotepa 100 mg powder for injection vial | 1993 | 10 |
| mitozantroneMITOZANTRONE EBEWE mitozantrone (as hydrochloride) 10mg/5mL solution f | 2001 | 6 |
| epirubicinEPIRUBICIN ACCORD epirubicin hydrochloride 10mg/5mL concentrated injec | 1992 | 5 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.